top of page

LATEST NEWS

August 2023

  • All the links have been checked and are properly working. 

June 2023:

  • All the links have been checked and are working properly.

  • The number of current clinical trials was updated accordingly.

  • New links were added for the “Compound Name” for: STRO-002, Cofetuzumab pelidotin, and STI-6129.

April 2023

  • Link for Cofetuzumab pelidotin’s “Company/Institution” has been updated with AbbVie's current pipeline webpage. All other links have been checked and are properly working.

  • The number of current clinical trials was updated accordingly.

Points discussed during meeting:

  • PF-06804103: This compound has no more active clinical trials; it is not found in the Pipeline on Pfizer’s website anymore either. It was decided to remove this compound in the Phase 1 page.

  • SGN-CD228A: This compound’s Phase 1 study is “terminated”; however, it is still on the Pipeline under phase 1 on Seagen’s website. It was decided we should keep this compound in the Phase 1 page for some months.

February 2023

  • All the links have been checked and were working properly. 

  • The number of current clinical trials was updated accordingly.

  • Link has been updated to show the company's pipeline page for A-166. 

  • Compound name for MorAb-202 has been updated to Farletuzumab Ecteribulin (MorAb-202). 

  • New compound, EBC-129, has been added. 
     

December 2022 

All the links have been checked and were working properly. The number of clinical trials in Phase 1 is currently reflected on the website. Recent updates to phase 1 clinical trials include compounds completing phase 1, progressing to phase 2, and phase 3. 

  • ARX-788: has six trials in progress: 1 phase 1 trial, 5 phase 2 trials, and 1 phase 3 trial.   

  • XMT-153:  named upifitamab rilsodotin, has 2 phase 1 trials, 1 phase 2 trial and 1 phase 3 trial.  

  • MORAb-202: has 3 phase 2 trials, and 1 phase 1 trial.   

  • MRG003: has 5 phase 2 trials, and 1 phase 1 trial.  

  • RC-88: has 1 phase 2 trial, and 2 phase 1 trials.  

  • STI-6129:  3 Phase 2 trials, and 5 phase 1 trials.   

September 2022

Approved Marine Drugs
© 2021-2023 Marine Pharmacology
© 2021-2023 Marine Pharmacology
bottom of page